# 119-hr-1796: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

119-hr-1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025, is a 119th Congress bill sponsored by Rep. James, John [R-MI-10] (R-MI); status introduced; PRIA reads it as touching household money (as of 2026-04-21).

- Canonical: https://policyrisk.com/legislation/119-hr-1796
- As of: 2026-04-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-1796
- Congress: 119
- Title: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
- Status: introduced
- Introduced: 2025-03-03
- Sponsor: Rep. James, John [R-MI-10] (R-MI)
- Cosponsors: 6
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-04-21

## Summary

**Would reauthorize and expand the federal sickle cell demonstration program and boost its funding.** The bill would add explicit support for treating sickle cell disease and preventing and treating its complications, and it expresses a call for more research on heritable blood disorders. - Families and patients: People with sickle cell disease would get clearer federal support for both disease care and for preventing and treating complications. This targets better care and follow up for affected children and adults. - Researchers and providers: The program would allow grants, contracts, or cooperative agreements, so academic centers and health systems could receive federal grants or contracts to run projects. - Public health and state programs: Authorized funding rises to $8.2 million per year for 2025–2029, up from $4.5 million in the prior authorization, enabling expanded surveillance, prevention, and treatment activities. *Would authorize higher annual funding for the program — $8.2 million per year for 2025–2029 versus $4.5 million previously — increasing federal program outlays relative to the prior authorization.*

## Cosponsors (6)

- Rep. Veasey, Marc A. [D-TX-33] (D-TX), 2025-03-03T00:00:00.000Z
- Rep. Carter, Troy A. [D-LA-2] (D-LA), 2025-03-03T00:00:00.000Z
- Rep. Davis, Danny K. [D-IL-7] (D-IL), 2025-03-03T00:00:00.000Z
- Rep. Kiggans, Jennifer A. [R-VA-2] (R-VA), 2025-03-03T00:00:00.000Z
- Rep. Vindman, Eugene Simon [D-VA-7] (D-VA), 2025-08-15T00:00:00.000Z
- Rep. Bishop, Sanford D. [D-GA-2] (D-GA), 2026-01-16T00:00:00.000Z

## Provisions PRIA read

- More funding for sickle cell care: benefit, low. If enacted, this would boost federal support for the sickle cell demonstration program to about $8.205 million each year for 2025–2029, up from $4.455 million in 2019–2023. The program could award grants and cooperative agreements, not just contracts. It would also focus on treating sickle cell dis…

## Related bills

- 119-hr-9877: Health Equity and Accountability Act of 2026
- 119-hr-3151: SHIPS for America Act of 2025
- 119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
- 119-hr-2102: Major Richard Star Act
- 119-hr-2048: Metastatic Breast Cancer Access to Care Act
- 119-hr-909: Crime Victims Fund Stabilization Act of 2025

## Sources
- [119-hr-1796 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/1796)

## Related
- [119-hr-9877: Health Equity and Accountability Act of 2026](https://policyrisk.com/legislation/119-hr-9877)
- [119-hr-3151: SHIPS for America Act of 2025](https://policyrisk.com/legislation/119-hr-3151)
- [119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage A…](https://policyrisk.com/legislation/119-hr-842)
- [119-hr-2102: Major Richard Star Act](https://policyrisk.com/legislation/119-hr-2102)
- [119-hr-2048: Metastatic Breast Cancer Access to Care Act](https://policyrisk.com/legislation/119-hr-2048)
- [119-hr-909: Crime Victims Fund Stabilization Act of 2025](https://policyrisk.com/legislation/119-hr-909)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-1796 (as of 2026-04-21).